Summary & Overview
HCPCS Q5109: Injection, infliximab-qbtx (Ixifi), 10 mg
HCPCS Level II code Q5109 denotes the 10 mg unit of infliximab-qbtx (Ixifi), a biosimilar to reference infliximab used for intravenous infusion in autoimmune and inflammatory diseases. Nationally, biologic and biosimilar infusion products are significant contributors to specialty drug spend and outpatient infusion service utilization, making accurate coding important for reimbursement, utilization monitoring, and biosimilar adoption tracking.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Coverage policies and reimbursement practices for biosimilars vary by payer and influence site-of-care decisions and patient access.
Readers will find: a concise description of what Q5109 represents clinically and operationally; typical sites of service where the code is used (outpatient infusion centers, hospital outpatient departments, physician office infusion suites); and the scope of payer coverage considered. The publication will also summarize benchmarking considerations, common billing modifiers and coding contexts (where available), and policy developments that shape biosimilar billing and utilization. Data not provided in the input (such as associated taxonomies, ICD-10 mappings, or payer-specific rate tables) are noted as unavailable.
Billing Code Overview
HCPCS Level II code Q5109 represents the injection of infliximab-qbtx, a biosimilar product marketed as Ixifi, billed per 10 mg dose. This code denotes a biologic infusion product used in the treatment of autoimmune and inflammatory conditions for which infliximab is indicated.
Service Type: Drug administration (intravenous infusion) — biosimilar infliximab product
Typical Site of Service: Outpatient infusion center, hospital outpatient department, or physician office infusion suite
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with a chronic immune-mediated inflammatory condition such as rheumatoid arthritis, Crohn disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, or plaque psoriasis who requires intravenous biologic therapy. The patient arrives at an outpatient infusion center or hospital outpatient department for administration of a biosimilar infliximab product (Q5109, infliximab-qbtx, ixifi) dosed per weight (typically 3–10 mg/kg depending on indication and protocol). Clinical workflow: the patient checks in, nursing performs pre-infusion assessment (vital signs, allergy review, medication reconciliation), pharmacy verifies and prepares the Q5109 syringe/vial dose, nursing obtains IV access and administers pre-medications if indicated (antihistamine, corticosteroid, acetaminophen), infuses Q5109 over the recommended infusion time with monitoring for infusion reactions, documents infusion start/stop times, monitors post-infusion recovery, and schedules the next dose. Typical sites of service are outpatient infusion centers, hospital outpatient departments, and ambulatory clinics with infusion capabilities. Common patient scenarios include maintenance therapy after induction, dose escalation for loss of response, or switch from reference infliximab to the biosimilar for non-medical or medical reasons.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|